Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Company Deals

Henlius and Sandoz Strike Strategic Biosimilars Deal Covering Up to 10 mAb and ADC Products Worth USD 314 Million for Initial Assets

Fineline Cube Aug 17, 2026
Drug Medical Device Policy / Regulatory

Guangdong Regulator Issues Recall, Traceability and Emergency Response Rules for Imported Hong Kong–Macao Pharmaceuticals and Medical Devices in GBA

Fineline Cube Aug 17, 2026
Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Fineline Cube Aug 18, 2026
Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Fineline Cube Aug 18, 2026
Company Drug

Zelgen Biopharmaceuticals’ Jacktinib Studies Selected for EHA Annual Meeting

Fineline Cube May 17, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that the results of three clinical...

Company Drug

Zelgen Biopharmaceuticals’ ZG0895 Receives FDA Approval for Clinical Trials in Advanced Solid Tumors

Fineline Cube May 16, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Company Deals

Coherent Biopharma Secures $100 Million in Series B and B+ Financings for Clinical Pipeline

Fineline Cube May 16, 2023

Coherent Biopharma Ltd, a specialist in bispecific-ligand drug conjugates (Bi-XDC) headquartered in Suzhou, has declared...

Company Legal / IP

Philips Agrees to $62 Million Settlement with SEC Over China Marketing Practices

Fineline Cube May 16, 2023

The US Securities and Exchange Commission (SEC) has announced that Dutch device company Philips (BVMF:...

Company Deals

Drug Farm Secures $27 Million in Series C Financing to Advance HBV Treatments

Fineline Cube May 16, 2023

Drug Farm, a Sino-US biotech company specializing in hepatitis B virus (HBV) treatments, oncology, and...

Company Medical Device

Peijia Medical Achieves Milestone with First Commercial Implants of Trilogy TAVR System in Hong Kong

Fineline Cube May 16, 2023

Peijia Medical Limited (HKG: 9996), a leading China-based medical device company, has announced the successful...

Company Deals

BiOneCure Therapeutics and Nanjing Leads Biolabs Collaborate on Innovative ADCs for Solid Tumors

Fineline Cube May 16, 2023

US-based biotech company BiOneCure Therapeutics Inc. has entered into a strategic collaboration with China-based Nanjing...

Company Drug

Lynk Pharmaceuticals’ LNK01001 Demonstrates Efficacy in Phase II Rheumatoid Arthritis Study

Fineline Cube May 16, 2023

China-based Lynk Pharmaceuticals Co., Ltd announced positive results from the Phase II clinical study of...

Company Drug

Skyline Therapeutics Initiates Clinical Study with First Patient Dosing of SKG0106 for wAMD

Fineline Cube May 16, 2023

Skyline Therapeutics has reached a significant milestone with the completion of the first patient dosing...

Company Drug

Gracell Biotechnologies Initiates Trial for GC012F in Refractory SLE with Dual-Target FasTCAR Therapy

Fineline Cube May 16, 2023

Gracell Biotechnologies Inc., (Nasdaq: GRCL), a China-based biopharmaceutical company, has announced the start of an...

Company Deals

Aligos Therapeutics Partners with Amoytop Biotech for Oligonucleotide Compound R&D

Fineline Cube May 16, 2023

Liver and viral disease specialist Aligos Therapeutics (NASDAQ: ALGS) announced last week a significant partnership...

Company Drug

CIM’s Cancer Vaccine CIMAvax Confirmed Immunogenic in US Study, Cuba Announces

Fineline Cube May 16, 2023

The Cuba-based Molecular Immunology Center (CIM), part of the state-run conglomerate BioCubaFarma, has shared updates...

R&D

COVID-19 Disruptions Lead to Soaring Lab Monkey Prices, Impacting US Drug Development

Fineline Cube May 16, 2023

The COVID-19 pandemic has led to a significant reduction in the export of laboratory monkeys...

Company Drug

Huadong Medicine’s HDM1002 Receives FDA Approval for Clinical Trials

Fineline Cube May 16, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it...

Company Deals

Rona Therapeutics and Keymed Biosciences Collaborate on siRNA Therapeutics for Glomerulonephritis

Fineline Cube May 15, 2023

China-based Rona Therapeutics Inc. and Keymed Biosciences (HKG: 2162) have unveiled a strategic collaboration aimed...

Company Deals Digital

Omron Healthcare and JD Healthcare Form Partnership to Innovate Chronic Disease Management

Fineline Cube May 15, 2023

At the China International Medical Equipment Fair (CMEF), Omron Healthcare, a leading provider of healthcare...

Company Deals

LaNova Medicines and AstraZeneca Ink Global Licensing Deal for GPRC5D-Targeting ADC LM-305

Fineline Cube May 15, 2023

Shanghai-based LaNova Medicines Ltd, a developer of cancer therapies, has announced a significant global licensing...

Company Deals

ExoRNA Bio Secures Tens of Millions in Financing to Advance Huntington’s Disease Pipeline

Fineline Cube May 15, 2023

ExoRNA Bio, a Shenzhen-based central nervous system (CNS) drug developer, has reportedly raised tens of...

Company Deals

Luye Pharma’s Boan Biotechnology Partners with GenScript on GenCircle dsDNA Development

Fineline Cube May 15, 2023

Shandong Boan Biotechnology Co., Ltd, a controlling subsidiary of China-based Luye Pharma Group (HKG: 2186),...

Company Drug

Betta Pharmaceuticals and EyePoint Pharmaceuticals Submit EYP-1901 for NMPA Review

Fineline Cube May 15, 2023

China’s Betta Pharmaceuticals (SHE: 300558) has announced that the clinical trial filing for its EYP-1901...

Posts pagination

1 … 569 570 571 … 709

Recent updates

  • OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties
  • European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets
  • Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform
  • Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors
  • CANbridge Pharmaceuticals’ Livmarli Granted NHIA Reimbursement Approval in Taiwan – IBAT Inhibitor Coverage for ALGS and PFIC Takes Effect September 1
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Company Drug

European Commission Revokes EU Marketing Authorisation for CSL and VFMCRP’s TAVNEOS – Avacopan Withdrawn Across EU and EEA Markets

Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Company Drug

Shanghai Yizhong’s First‑in‑Class Tri‑Specific Biologic YXC‑001 Wins NMPA Clinical Trial Approval for Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.